XML 45 R24.htm IDEA: XBRL DOCUMENT

Related Party Transactions

12 Months Ended

Dec. 31, 2019

17.	Related Party Transactions

As described in Note 12, in January 2016 the Company entered into a License Agreement and, in November 2018, a letter agreement with NHS for the development and commercialization of certain product candidates in development for the treatment and management of CDI and IBD, including UC and Crohn’s disease. NHS is a related party since NHS is an affiliate of Nestlé Health Science, one of the Company’s significant stockholders. During the years ended December 31, 2019, 2018, and 2017, the Company recognized $27,188, $26,917, and $32,100, respectively, of related party revenue associated with the License Agreement. As of December 31, 2019 and 2018, there was $110,071 and $137,259, respectively, of deferred revenue related to the License Agreement, which is classified as current or non-current in the consolidated balance sheets. The Company has made no payments to NHS during the year ended December 31, 2019. There is no amount due from NHS as of December 31, 2019.

In July 2019, the Company entered into a sublease agreement with Flagship Pioneering, one of the Company’s significant stockholders, to sublease a portion of its office and laboratory space in Cambridge, Massachusetts. The term of the sublease agreement commenced in July 2019 and ends on the last day of the 24th calendar month following commencement, with no option to extend (see Note 7). Under this agreement, the Company recorded other income of $890 during the twelve months ended December 31, 2019. The Company received cash payments of $890 during the twelve months ended December 31, 2019.